Whitfield Dianne C.

CHRO Whitfield sells 12,274 shares over 3 days for $839,069.59; prior same-ticker sales show consistent 30-day declines (-8.0% to -22.2%)

Dianne C. Whitfield, Chief Human Resources Officer at Tarsus Pharmaceuticals (TARS), executed 3 separate sales totaling 12,274 shares for $839,069.59 between March 17–19, 2026, at prices ranging from $67.00 to $69.42 (blended $68.36). This represented a 25.9% reduction in her holdings from 47,302 to 35,028 shares. The current stock price is $66.75, already below the sales prices and down 18.0% over 90 days, while the company remains unprofitable with negative $12.6M net income despite strong 146.7% annual revenue growth. Her prior 5 sales at TARS (since December 16, 2025) all showed negative 30-day returns, ranging from -8.0% to -22.2%, establishing a consistent pattern at this ticker. Cross-ticker, her track record shows a 100.00% well-timed sell rate (90-day metric), though the small prior sample size and the company's current unprofitability suggest investors should monitor whether this latest tranche follows the same post-sale decline pattern evident in her recent activity at TARS.

CHRO Whitfield sells 15,565 shares at $80.67 avg ($1.3M); reduces stake 40% to 23,393 shares

Whitfield Dianne C., Chief Human Resources Officer at Tarsus Pharmaceuticals, executed 4 separate sales on 2026-01-02 totaling 15,565 shares for $1,255,683.96, reducing her holdings by 40% from 38,958 to 23,393 shares. The blended average sale price of $80.67 sits slightly above the current price of $79.88, near the 52-week high of $82.51. Notably, the company generated $118,697,000.00 in revenue last quarter with annual revenue growth of +948.6%, yet reported a net loss of $-12,585,000.00 and remains unprofitable on a full-year basis. The prior sell at this ticker (2025-12-16) occurred 17 days before this filing, and the insider's overall cross-ticker track record shows only 1 prior sell, providing limited pattern history for contextual assessment.

CHRO Whitfield sold 7,397 shares ($592.5K) at $80.10; holds 38,958 shares post-sale in unprofitable biotech.

Whitfield Dianne C., Chief Human Resources Officer, sold 7,397 shares (39% of holdings pre-transaction) at $80.10 on 2025-12-16, reducing her stake from 46,355 to 38,958 shares. The transaction occurred near the 52-week high of $82.23, just -5.8% below peak valuation in a company trading at $77.48 today. Despite exceptional annual revenue growth of +948.6% and a $3.3B market cap, Tarsus Pharmaceuticals posted negative net income of $-12.6M in its most recent quarter and remains unprofitable on a full-year basis, highlighting execution risk in a hypergrowth phase. The CHRO's material reduction in personal exposure warrants monitoring given the company's profitability challenges and the execution demands of integrating such rapid revenue expansion.